Table 2.

Multivariate analysis of breast cancer-specific mortality by HSF1 status (positive or negative)

	n		HR (95% CI)
Models	Cases	Endpoints	HSF1-negative	HSF1-positive
All cases
Model 1	1,841	463	1.00	1.74 (1.35–2.25)
Model 2	1,841	463	1.00	1.50 (1.15–1.95)
ER-positive cases
Model 1	1,416	327	1.00	2.21 (1.60–3.06)
Model 3	1,416	327	1.00	1.86 (1.34–2.59)
ER-negative cases
Model 1	403	135	1.00	0.86 (0.56–1.32)
Model 3	403	135	1.00	0.88 (0.570–1.39)
HER2-positive cases
Model 1	194	71	1.00	2.06 (0.83–5.12)
Model 2	194	71	1.00	2.87 (1.12–7.39)
HER2-negative cases
Model 1	1,621	386	1.00	1.61 (1.23–2.11)
Model 2	1,621	386	1.00	1.37 (1.04–1.80)
Triple-negative cases
Model 1	268	86	1.00	0.88 (0.52–1.50)
Model 3	268	86	1.00	0.88 (0.50–1.53)
ER-positive with hormone therapy cases
Model 1	700	122	1.00	2.77 (1.52–5.02)
Model 4	700	122	1.00	2.20 (1.19–4.05)
ER-positive without hormone therapy cases
Model 1	247	38	1.00	3.22 (1.14–9.10)
Model 4	247	38	1.00	2.01 (0.69–5.88)

Model 1: adjust for age at diagnosis (years); model 2: adjust for age at diagnosis (years), ER status (positive, negative), date of diagnosis (months), disease stage (I, II, III), grade (I, II, III), radiation treatment (yes, no, missing), and chemotherapy and hormonal treatment (no/no, yes/no, no/yes, yes/yes, missing); model 3: adjust for age at diagnosis (years), date of diagnosis (months), disease stage (I, II, III), grade (I, II, III), radiation treatment (yes, no, missing), and chemotherapy and hormonal treatment (no/no, yes/no, no/yes, yes/yes, missing); model 4: adjust for age at diagnosis (years), date of diagnosis (months), disease stage (I, II, III), grade (I, II, III), radiation treatment (yes, no, missing), and chemotherapy (yes, no, missing).